Document is current
Any future updates will be listed below
-
Authors
Park, Sarah E.
Masson, Rahul
Shih, Terri
Shi, Vivian Y.
Hsiao, Jennifer L.
Aleshin, Maria A.
- License Information
-
More Information
Article History
Received: 22 September 2023
Revised: 20 October 2023
Accepted: 9 November 2023
First Online: 4 December 2023
Declarations
:
: VYS is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. JLH is on the board of directors for the Hidradenitis Suppurativa Foundation, has served as a consultant for Aclaris, AbbVie, Boehringer Ingelheim, Incyte, Novartis, and UCB; as a speaker for AbbVie; as an investigator for Amgen, Boehringer Ingelheim, and Incyte. MA has served as a consultant for AbbVie, Novartis, Santa Ana Bio and has received research funding from UCB. All other authors report no conflicts of interest.
